Innovation Medical(SZ:002173) Zheng Quan Zhi Xing·2025-08-09 22:25Core Viewpoint - Innovation Medical (002173) reported a slight decline in total revenue for the first half of 2025, but showed improvement in net profit and profitability metrics compared to the previous year [1]. Financial Performance - Total revenue for the first half of 2025 was 402 million yuan, a decrease of 1.6% year-on-year [1]. - The net profit attributable to shareholders was -11.36 million yuan, an increase of 29.12% year-on-year [1]. - In Q2 2025, total revenue was 208 million yuan, an increase of 0.73% year-on-year [1]. - Q2 2025 net profit attributable to shareholders was 2.58 million yuan, an increase of 119.74% year-on-year [1]. Profitability Metrics - Gross margin increased by 2.27% year-on-year to 12.06% [1]. - Net margin improved by 28.4% year-on-year, reaching -2.79% [1]. - Total selling, administrative, and financial expenses amounted to 55.73 million yuan, accounting for 13.88% of revenue, an increase of 10.15% year-on-year [1]. Cash Flow and Assets - Operating cash flow per share was 0.19 yuan, a significant increase of 2578.88% year-on-year [1]. - Cash and cash equivalents decreased by 55.17% year-on-year to 249 million yuan [1]. - Accounts receivable decreased by 39.67% year-on-year to 74.89 million yuan [1]. Debt and Financial Health - Interest-bearing debt decreased by 4.71% year-on-year to 63.75 million yuan [1]. - The company has a healthy cash asset position, indicating good liquidity [2]. Historical Performance - The company has a poor historical return on invested capital (ROIC), with a median of -4.26% over the past decade [1]. - The company has reported losses in 8 out of 17 annual reports since its listing, indicating a generally weak financial performance [1].